What the FDA labels say about taking them together
Levodopa and selegiline
Selegiline's FDA label (Zelapar) of June 1, 2021 names levodopa in its warnings and precautions section; levodopa's label does not name selegiline itself but warns about its class (MAO inhibitors).
Check it at the source: the levodopa FDA label on DailyMed (effective July 20, 2026, Merz Pharmaceuticals, LLC); the selegiline FDA label on DailyMed (effective August 7, 2024, Rising Pharma Holdings, Inc.).
What does the levodopa label say about selegiline?
Levodopa's label does not name selegiline itself; it warns about its class (MAO inhibitors):
Levodopa label, contraindicationsCONTRAINDICATIONS INBRIJA is contraindicated in patients currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine and tranylcypromine) or who have recently (within 2 weeks) taken a nonselective MAO inhibitor.
Levodopa label, drug interactionsOxidase (MAO) Inhibitors The use of nonselective MAO inhibitors with INBRIJA is contraindicated [see Contraindications (4) ].
Source: FDA drug label (Inbrija), Merz Pharmaceuticals, LLC, effective July 20, 2026 (SPL set 077c0f39-a3a2-4b2b-a184-09131889dcfb), via openFDA; the full label on DailyMed
What does the selegiline label say about levodopa?
Zelapar label (Bausch Health US, LLC, June 1, 2021), warnings and precautionsDyskinesia ZELAPAR may potentiate dopaminergic side effects of levodopa and may cause dyskinesia or exacerbate preexisting dyskinesia.
Source: FDA drug label (Zelapar, NDA021479), Bausch Health US, LLC, effective June 1, 2021 (SPL set 380d7717-2a79-42f3-a712-efe5e7696ba0), via openFDA
Source: FDA drug label (Selegiline Hydrochloride), Rising Pharma Holdings, Inc., effective August 7, 2024 (SPL set 23c4481f-d150-40c6-addb-b3e454ca914f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Levodopa | Selegiline | |
|---|---|---|
| Labeled for | Parkinson's disease | Parkinson's disease, Depression |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $0.756 per capsule 5 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once